Azuria_WS_RGB_pos (1).png
Azuria Water Solutions Announces Acquisition of Pipe Pros LLC
20 déc. 2024 10h40 HE | Azuria Water Solutions
Azuria Water Solutions announces the acquisition of Pipe Pros LLC
Azuria_WS_RGB_pos (1).png
Azuria Water Solutions Announces the Acquisition of a portion of Miller Pipeline’s Municipal Services Division
06 nov. 2024 09h00 HE | Azuria Water Solutions
Azuria Water Solutions™ today announced the acquisition of a portion of Miller Pipeline LLC’s municipal services division operations.
Tevogen Logo Notified.png
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
11 oct. 2024 15h59 HE | Tevogen Bio Inc
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
11 oct. 2024 12h12 HE | Tevogen Bio Inc
Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.Expanding its pipeline to include non-oncology products, an opportunistic...
Mural_Logo.jpg
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
26 sept. 2024 07h00 HE | Mural Oncology, Inc.
Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...
barinthuslogo.jpg
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12 juin 2024 16h01 HE | Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Azuria_WS_RGB_pos (1).png
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
11 juin 2024 10h36 HE | Azuria Water Solutions
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
03 juin 2024 08h14 HE | AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
Mural_Logo.jpg
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
23 mai 2024 17h00 HE | Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Mural_Logo.jpg
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 07h00 HE | Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.